NCT07703735Enrolling by invitation
Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 371 (estimated)
- First submitted
- 7 Jul 2026
- Start date
- 1 Jan 2012
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Seoung Hoon Kim
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07703735
What you commit to
- Study type: Observational
- Planned participants: 371
- From 1 Jan 2012 to the primary completion date, 31 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- • Deceased donor liver transplantation
- Re-transplantation
Who the study is looking for
- Underwent living donor liver transplantation for HCC
- Transplantation between Jan 2012 - Dec 2023
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.